Liquidia Technologies (LQDA)
(Real Time Quote from BATS)
$10.03 USD
+0.10 (1.01%)
Updated Sep 24, 2024 11:14 AM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
Liquidia Technologies, Inc. [LQDA]
Reports for Purchase
Showing records 1 - 20 ( 133 total )
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Topical Legal Developments in the Yutrepia Saga Patent Attorney''s Take on Latest Lawsuit; Reit. Buy and $29 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Patent Attorney''s Comments on Tentative FDA Approval of Yutrepia in Both PAH and PH-ILD; Dec. PT Down to $29, Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Yutrepia Remains in Limbo Optimistic on FDA Final Approval in Both PAH and PH-ILD; Reiterate Buy and $32 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
The Wait for Yutrepia Approval Continues?Remain Optimistic on FDA Final Approval in Both PAH and PH-ILD; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY23 Financials; Updates on Ongoing Litigation withUnited, Reiterate UP
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Yutrepia Approaches FDA Approvals-Raising Market Assumptions; Reit. Buy and Raising PT to $32
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
FDA Adds Fuel to the Fire, Extends YUTREPIA NDA Review Amid Ongoing Litigation
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
David Goliath Showdown Continues: Federal Circuit Affirms ''793 PTAB Decision
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Federal Circuit Affirms ''793 PTAB Decision; Tyvaso DPI''s Dominance to Persist
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for LQDA 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Q3: Another Layer of Patent Litigation Added to the Ongoing Battle with United
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Near-Term Sights on ?793 Patent and Federal Circuit-Potential Yutrepia Expansion; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Q2: Twists Turns Added to the Litigation Labyrinth, Launch Timing Unclear
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Ongoing Yutrepia Litigation for ?793 Patent-Remaining Gating to Approval; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A